Fisher Asset Management LLC Has $18.55 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Fisher Asset Management LLC increased its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 6.8% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 324,005 shares of the biopharmaceutical company's stock after acquiring an additional 20,721 shares during the period. Fisher Asset Management LLC owned about 0.25% of Halozyme Therapeutics worth $18,546,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. GAMMA Investing LLC raised its stake in shares of Halozyme Therapeutics by 96.6% in the 2nd quarter. GAMMA Investing LLC now owns 517 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 254 shares during the period. International Assets Investment Management LLC acquired a new stake in Halozyme Therapeutics in the 2nd quarter valued at approximately $33,000. Skandinaviska Enskilda Banken AB publ acquired a new position in Halozyme Therapeutics during the 2nd quarter worth approximately $49,000. Toth Financial Advisory Corp acquired a new position in Halozyme Therapeutics during the 3rd quarter worth approximately $57,000. Finally, FSC Wealth Advisors LLC bought a new position in shares of Halozyme Therapeutics during the 3rd quarter worth approximately $65,000. 97.79% of the stock is owned by institutional investors.

Insider Activity

In related news, CEO Helen Torley sold 10,000 shares of the firm's stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $59.20, for a total transaction of $592,000.00. Following the transaction, the chief executive officer now directly owns 676,744 shares of the company's stock, valued at approximately $40,063,244.80. This trade represents a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 60,000 shares of company stock valued at $3,425,000. 2.70% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on HALO. Wells Fargo & Company downgraded shares of Halozyme Therapeutics from an "overweight" rating to an "equal weight" rating and raised their target price for the company from $58.00 to $62.00 in a research report on Monday, October 7th. Piper Sandler raised their price objective on Halozyme Therapeutics from $51.00 to $52.00 and gave the company a "neutral" rating in a report on Monday, November 4th. HC Wainwright reissued a "buy" rating and set a $68.00 price target on shares of Halozyme Therapeutics in a research report on Wednesday, November 20th. Cowen restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. Finally, JPMorgan Chase & Co. cut Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and upped their price objective for the stock from $52.00 to $57.00 in a research note on Thursday, September 19th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $61.11.

Halozyme Therapeutics Stock Performance

Shares of NASDAQ HALO traded up $0.68 during trading hours on Thursday, reaching $48.47. 963,013 shares of the stock were exchanged, compared to its average volume of 1,375,309. The firm has a market capitalization of $6.17 billion, a price-to-earnings ratio of 16.05, a P/E/G ratio of 0.43 and a beta of 1.29. The stock's fifty day simple moving average is $53.72 and its 200 day simple moving average is $53.67. The company has a debt-to-equity ratio of 3.32, a quick ratio of 9.15 and a current ratio of 10.36. Halozyme Therapeutics, Inc. has a 52 week low of $33.15 and a 52 week high of $65.53.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.